Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.

Investigational new drugs - 1 Aug 2004

Sparreboom Alex, Marsh Sharon, Mathijssen Ron H J, Verweij Jaap, McLeod Howard L

Abstract excerpt

The purpose of this study was to perform exploratory relationships between the pharmacokinetics of the farnesyl transferase inhibitor, tipifarnib (R115777, Zarnestra) and allelic variants of genes coding for ATP binding-cassette transporters and drug-metabolizing enzymes. Twenty-eight patients with advanced solid tumors were treated with tipifarnib administered orally at a dose of 200 or 300 mg. Blood samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Glucuronosyltransferase

Share to Pharmacogenetics

Share to Quinolones

Share to Tandem Repeat Sequences

Source

Identifiers

PMID: 15122075
DOI: 10.1023/B:DRUG.0000026254.97350.fe

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.PMID 15122075Read ↗

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.Semantic proximity Read ↗

SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.Semantic proximity Read ↗

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.Semantic proximity Read ↗

Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.Semantic proximity Read ↗

Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.Semantic proximity Read ↗

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.Semantic proximity Read ↗

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.Semantic proximity Read ↗

Pharmacogenetics of irinotecan metabolism and transport: an update.Semantic proximity Read ↗

Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of ABCB1 3435C>T and ABCB1 2677G>T/A.Semantic proximity Read ↗

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.